# Roginolisib

Source: https://onco.cc/drugs/roginolisib/  
OnCo record `roginolisib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Roginolisib is an oral pi3k inhibitor from iOnctura, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.

## Summary

Roginolisib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by iOnctura, in non-small-cell lung cancer, small-cell lung cancer. A phosphoinositide 3-kinase inhibitor: the name stem -lisib marks a small molecule that blocks PI3K signalling. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Also known as: IOA-244
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Oral PI3K inhibitor
- Mechanism: A phosphoinositide 3-kinase inhibitor: the name stem -lisib marks a small molecule that blocks PI3K signalling.

## Sources

- ClinicalTrials.gov: trials of roginolisib: https://clinicaltrials.gov/search?intr=roginolisib

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- companies: [iOnctura](https://onco.cc/companies/ionctura/)
- trials: [A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma](https://onco.cc/trials/nct06717126/), [A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients](https://onco.cc/trials/nct06879717/)

---
JSON: https://onco.cc/api/v1/entities/roginolisib.json